News
TPTX
76.01
0.00%
0.00
Bristol Myers' $4.1B Turning Point acquisition gets clearance in US, Germany, set to close
Bristol Myers Squibb's (NYSE:BMY) $4.1B <a href="http...
Seekingalpha · 08/16 11:45
Bristol Myers Squibb And Turning Point Therapeutics Announce Expiration Of HSR Act Waiting Period And Clearance From Federal Cartel Office Of Germany Related To Pending Acquisition Of Turning Point Therapeutics
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements
Benzinga · 08/16 11:00
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday
MT Newswires · 08/16 07:59
Turning Point Therapeutics GAAP EPS of -$2.48 misses by $0.78, revenue of $0.12M misses by $2.15M
Turning Point Therapeutics press release (<s...
Seekingalpha · 08/08 20:46
BRIEF-Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of Ros1+ Advanced Nsclc
BRIEF-Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of Ros1+ Advanced Nsclc
Reuters · 07/27 22:16
Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission
Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter.
Benzinga · 07/27 20:45
Turning Point Therapeutics Provides Regulatory Update For Repotrectinib For The Treatment Of ROS1+ Advanced NSCLC
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the
Benzinga · 07/27 20:22
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDASAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developi...
GlobeNewswire · 07/27 20:05
Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?
Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.
Zacks · 07/25 16:41
Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report
Bristol Myers  Squibb (NYSE:BMY) is reportedly expect...
Seekingalpha · 07/21 19:40
Bristol Myers extends tender offer period for $4.1B Turning Point acquisition
Bristol Myers Squibb (NYSE:BMY) <a href="https://seek...
Seekingalpha · 07/19 12:09
BRIEF-Bristol Myers Squibb Announces Extension Of Turning Point Tender Offer
BRIEF-Bristol Myers Squibb Announces Extension Of Turning Point Tender Offer
Reuters · 07/19 11:11
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
Bristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. ("Offeror"), a wholly owned subsidiary of Bristol Myers Squibb, has extended the expiration date of its offer (the
Benzinga · 07/19 10:59
BRIEF-Turning Point Therapeutics And MD Anderson Announce Alliance
reuters.com · 06/24 13:32
Turning Point Therapeutics And MD Anderson Announce Strategic Alliance To Advance Precision Cancer Therapies
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD Anderson Cancer
Benzinga · 06/24 13:02
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, and The University of Texas MD And...
GlobeNewswire · 06/24 13:00
IBD Stock Of The Day: Bristol Myers Eyes Breakout After $4.1 Billion Buyout
Bristol Myers Squibb is the IBD Stock Of The Day as BMY stock bounds off its 50-day line, presenting investors with an early entry.
Investor's Business Daily · 06/22 21:19
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2022
Upgrades
Benzinga · 06/13 15:05
--Guggenheim Downgrades Turning Point Therapeutics to Neutral From Buy, Adjusts Price Target to $76 From $72
MT Newswires · 06/13 12:11
SVB Securities Downgrades Turning Point Therapeutics to Market Perform From Outperform, Adjusts Price Target to $76 From $101
MT Newswires · 06/13 08:59
More
Webull provides a variety of real-time TPTX stock news. You can receive the latest news about Turning Point Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About TPTX
Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. It develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company’s drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company’s pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.